Trial Search Results

Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)

A research study using a method of treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Diagnostic Test: PET Scan
  • Diagnostic Test: CT Scan
  • Radiation: SABR

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Limited primary or metastatic lung tumors with no evidence of uncontrolled
   extrathoracic metastases

   - Up to 4 lesions may be included, with none larger than 5 cm if there are more than
   one, or up to 7 cm if there is a single tumor

   - Both peripheral and central tumors are accepted for this trial.

   - Age > 18 years old

   - Both men and women and members of all races and ethnic groups are eligible for this
   trial.

   - Note: Patients may be enrolled more than once (e.g. for a new tumor)

Exclusion Criteria:

   - Evidence of uncontrolled extrathoracic metastases

   - Contraindication to receiving radiotherapy.

   - Contraindication to receiving radiotherapy

   - Age < 18 years old. Children are excluded because lung malignancies rarely occur in
   this age group. Furthermore, treatment requires a great deal of patient cooperation
   including the ability to lie still for several hours in an isolated room.

   - Pregnant and breastfeeding women are excluded; as well as women of child-bearing
   potential who are unwilling or unable to use an acceptable method of birth control
   (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the
   duration of the study. Male subjects must also agree to use effective contraception
   for the same period as above. Should a woman become pregnant or suspect she is
   pregnant while participating in this study, she should inform her treating physician
   immediately.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rachel Freiberg
650-725-0438
Recruiting